Study wrapper · #458
LAT1-mediated delivery of engineered R13A-MOTS-c attenuates radiation-induced lung injury via Nrf2 activation and mitochondrial protection.
Editor's note
A preclinical study engineering a modified MOTS-c (R13A-MOTS-c) to improve cell uptake, then testing it against radiation-induced lung injury. In cells and in C57BL/6 mice given thoracic irradiation, daily intraperitoneal R13A-MOTS-c (5 mg/kg for two weeks) was associated with reduced lung inflammation, oxidative stress and mitochondrial dysfunction, with effects tied to activation of the Nrf2 antioxidant pathway and lost when Nrf2 or the LAT1 transporter were blocked. These are preclinical findings; human data are needed before clinical conclusions can be drawn. Two specifics matter for readers: the agent is an engineered analog, not native MOTS-c, so results may not transfer to the unmodified peptide, and the model is acute radiation injury in mice. This is a mechanistically detailed signal for MOTS-c-based approaches, useful as hypothesis-generating context, not evidence of benefit in people.
Plain-language abstract
MOTS-c is a small natural peptide with antioxidant and anti-inflammatory properties, but it does not easily get into cells. To fix that, researchers created a modified version, called R13A-MOTS-c, that enters cells more readily. They then tested it against lung injury caused by radiation. In lab-grown lung cells and in mice given a high dose of chest radiation, daily injections of the modified peptide (into the abdomen, for two weeks) reduced lung inflammation, oxidative damage and mitochondrial problems. The protective effect worked through a cellular defense system called Nrf2 and depended on a specific transporter that carries the peptide into cells; blocking either one removed the benefit. Because this was done in cells and mice using an engineered version of the peptide rather than the natural form, the results cannot be assumed to apply to people or to standard MOTS-c. The authors present it as a promising strategy that needs much more research.